Amphastar Pharmaceuticals (AMPH) Total Liabilities (2013 - 2026)

Amphastar Pharmaceuticals' Total Liabilities history runs 14 years deep, the most recent figure standing at $874.8 million for Q1 2026.

• On a quarterly basis, Total Liabilities changed 0.03% year-over-year to $874.8 million in Q1 2026; TTM through Mar 2026 was $874.8 million, a 0.03% change from a year earlier, with the FY2025 full-year figure at $840.5 million, down 0.55% from the prior year.
• Total Liabilities rose to $874.8 million in Q1 2026 per AMPH's latest filing, from $840.5 million in the prior quarter.
• Across five years, Total Liabilities topped out at $949.5 million in Q3 2023 and bottomed at $213.3 million in Q4 2022.
• The 5-year median for Total Liabilities is $840.5 million (2025), against an average of $671.4 million.
• Across the five-year window, Total Liabilities soared 328.61% in 2023 and dropped 13.9% in 2024, its largest moves.
• Year by year, Total Liabilities stood at $213.3 million in 2022, then surged by 309.46% to $873.5 million in 2023, then fell by 3.24% to $845.2 million in 2024, then fell by 0.55% to $840.5 million in 2025, then increased by 4.08% to $874.8 million in 2026.
• Per Business Quant, the three latest AMPH Total Liabilities figures stand at $874.8 million (Q1 2026), $840.5 million (Q4 2025), and $889.5 million (Q3 2025).